PHP
TELA icon

Parkman Healthcare Partners’s TELA Bio TELA Stock Holding History

Parkman Healthcare Partners’s Portfolio TELA Stock Details TELA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-97,816
Closed -$460K – 103
2024
Q2 		$460K Buy
97,816
+148
+0.2% +$780 0.06% 88
2024
Q1 		$554K Sell
97,668
-5,707
-6% -$37.6K 0.07% 97
2023
Q4 		$684K Sell
103,375
-63,350
-38% -$366K 0.1% 84
2023
Q3 		$1.33M Buy
166,725
+7,699
+5% +$71.5K 0.24% 88
2023
Q2 		$1.61M Buy
159,026
+21,654
+16% +$221K 0.28% 83
2023
Q1 		$1.46M Buy
137,372
+20,704
+18% +$228K 0.32% 68
2022
Q4 		$1.34M Buy
116,668
+6,388
+6% +$57.2K 0.36% 67
2022
Q3 		$940K Buy
110,280
+1,296
+1% +$10.7K 0.27% 72
2022
Q2 		$764K Buy
108,984
+480
+0.4% +$3.98K 0.28% 63
2022
Q1 		$1.26M Buy
108,504
+4,222
+4% +$51.1K 0.37% 60
2021
Q4 		$1.33M Buy
104,282
+4,282
+4% +$54.2K 0.29% 69
2021
Q3 		$1.37M Hold
100,000
– – 0.35% 60
2021
Q2 		$1.61M Buy
+100,000
New +$1.37M 0.35% 66
2020
Q1 		– Sell
-25,000
Closed -$324K – 73
2019
Q4 		$324K Buy
+25,000
New +$306K 0.09% 68

Other funds holding TELA

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Parkman Healthcare Partners's TELA Position: Q3 2024 in Review

Parkman Healthcare Partners sold out of TELA Bio (TELA) in Q3 2024, closing a stake of 97,816 shares — an estimated $460K sold.

Parkman Healthcare Partners first reported a position in TELA in Q4 2019 and held it in 14 quarters. The position peaked at $1.61M in Q2 2021. 49 funds tracked by Wall St. Rank hold TELA as of Q3 2024.

  • Parkman Healthcare Partners reported no remaining TELA Bio position as of Q3 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 97,816 TELA Bio shares in Q3 2024, an estimated $460K.
  • Parkman Healthcare Partners first reported a position in TELA Bio in Q4 2019 and held it in 14 quarters.
  • Parkman Healthcare Partners's TELA Bio position peaked at $1.61M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held TELA Bio as of Q3 2024.

Based on Parkman Healthcare Partners's 13F filing for Q3 2024, filed 14 Nov 2024.